SUPN - Supernus Pharmaceuticals Inc

https://www.supernus.com

Buy Momentum: Bearish

Recent News

Insider Decision: Frederick Hudson Offloads $315K Worth Of Supernus Pharmaceuticals Stock - Supernus Pharmaceuticals ( NASDAQ:SUPN )

Benzinga • 3 weeks, 6 days ago • score: 0.12

Making a noteworthy insider sell on August 18, Frederick Hudson, Director at Supernus Pharmaceuticals SUPN, is reported in the latest SEC filing. What Happened: Hudson's decision to sell 7,457 shares of Supernus Pharmaceuticals was revealed in a Form 4 filing with the U.S.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.

52W High

$46.10

52W Low

$29.16

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.79

Valuation

Fair

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

40.00

Forward P/E (<15 better)

20.16

EV/EBITDA (<8 favorable)

11.99

EV/Revenue (<3 favorable)

3.14

P/S (TTM) (<3 favorable)

3.88

P/B (<3 favorable)

2.42

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

4.20%

Institutions (25–75% balanced)

109.54%

Shares Outstanding

56,073,000

Float

48,892,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

665,125,000

Gross Profit (TTM)

588,854,000

EPS (TTM)

1.15

Profit Margin (>10% good)

0.10%

Operating Margin (TTM) (higher better)

0.07%

ROE (TTM) (>15% strong)

0.06%

EPS YoY (Quarterly) (>10% good)

0.11

Revenue YoY (Quarterly) (>8% good)

-0.02

Momentum

Bearish momentum

Value

2.1155

2.2981

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025